Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufacturing, and commercialization of innovative therapies. Patients in more than 90 countries benefit from Biogen Idec’s significant products that address diseases such as lymphoma, multiple sclerosis, and rheumatoid arthritis.
TODAY’S HEADLINES: Trius Therapeutics raises $30M for new antibiotics (release) Genomas gets $1.2M grant for genomic side-effect tests (release) Provasculon… Continue reading 〉
TODAY’S HEADLINES: CyberHeart pumps in $9M for cardiac-arrhythmia treatment (release) Incubator ForSight launches third device company with $6M funding (release)… Continue reading 〉